CSL Limited's Transformation Program targets $500–$550M in annual pre-tax cost reductions by FY28. Read why CSLLY stock is a ...

CSL Ltd (ASX: CSL) shares are down more than 50%. Here’s why this ASX healthcare blue chip could be a strong buy in May.

The Health Care (XHJ) industry slumped 0.01% to close at 25440.0. CSL Ltd closed $60.21 below its 52-week high ($184.62), which the company achieved on Tuesday, January 27. Trading volume of 1.4 ...

CSL (ASX:CSL) has outlined a restructuring plan that includes separating its Seqirus influenza vaccine business into a ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

By Rajasik Mukherjee April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

A casual enthusiast might tell you that BMW’s M-badged models are the company’s peak performance offerings. The true fans know that in reality, the rare CSL models are a cut above. In its latest video ...

New US-Iran missile attacks and an interest rate rise in Australia sent the market lower today. The post CSL and Wesfarmers among scores of ASX shares hitting fresh 52-week lows appeared first on The ...

Earlier this year, BMW debuted the M4 CS, a car designed to sit between the Competition Package and the ultra-hardcore M4 GTS. Of course, bringing back the CS designation, which stands for Coupe Sport ...